Perspective Therapeutics, Inc. (CATX) Research
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Market snapshot
- Symbol
- CATX
- Price
- $2.95
- Day change
- -1.01%
- Market cap
- $227.9M
- P/E ratio
- -0.03x
- 52-week range
- 1.96-6.16
- Sector
- Healthcare
- Industry
- Medical - Devices
- Next earnings
- in 2 months
- Analyst price target
- $13.33
Recent news
- Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that previously focused only on a different cancer type known as neuroendocrine tumors. The new arm of the Phase 1/2a study, called LEMONaDE, aims to assess how safe the treatment is and whether it shows early signs of shrinking tumors in meningioma patients.
- Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug...
Peer companies
Recent insider activity
- Martinez Maria E — A-Award (50000 shares) on 2026-03-02
- Morich Frank — A-Award (50000 shares) on 2026-03-02
- Williamson Robert F III — A-Award (50000 shares) on 2026-03-02
- HENSON HEIDI — A-Award (50000 shares) on 2026-03-02
- Woods Lori A — A-Award (50000 shares) on 2026-03-02
Open Perspective Therapeutics, Inc. (CATX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.